Evidence map›Paper›PMID 26497750›Full record

Trial reportBMC infectious diseases2015

Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom.

Douglas M Fleming, Robert J Taylor, Roger L Lustig, Cynthia Schuck-Paim, François Haguinet, David J Webb, John Logie, Gonçalo Matias, Sylvia Taylor

2 registry-linked trialsAbstract readClinical Trial
In one paragraph

Trial report in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01706302 completednot on this map

Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom, 1995 to 2009

TypeobservationalSponsorGlaxoSmithKlineRan2012 to 2012Enrolled1ConditionsRespiratory Syncyctial Virus VaccinesArmsData collection
NCT06286007 unknown statusnot on this mapstarted 2023, after this paper: background citation

Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control

Typeobservational_patient_registrySponsorHospital Clinico Universitario de SantiagoRan2023 to 2026Enrolled784ConditionsAsthma, Pertussis, RSV InfectionArmsPCR
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Review
  14. Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Douglas M FlemingIndependent Consultant, 9 Dowles Close, Birmingham, B29 4LE, United Kingdom. dmfleming9dc@btinternet.com.
Robert J TaylorSage Analytica, 4550 Montgomery Ave., Suite 4915 St. Elmo Ave, Ste. 205, Bethesda, MD 20814, USA. rtaylor@sageanalytica.com.
Roger L LustigSage Analytica, 4550 Montgomery Ave., Suite 4915 St. Elmo Ave, Ste. 205, Bethesda, MD 20814, USA. rlustig@sageanalytica.com.
Cynthia Schuck-PaimSage Analytica, 4550 Montgomery Ave., Suite 4915 St. Elmo Ave, Ste. 205, Bethesda, MD 20814, USA. Cynthia.schuck@gmail.com.
François HaguinetGSK Vaccines, Av Fleming 20, Parc de la Noire Epine, 1300, Wavre, Belgium. Francois.F.Haguinet@gsk.com.
David J WebbGSK Pharmaceuticals, Stockley Park West, 1-3 Ironbridge Road, Heathrow, Uxbridge, Middlesex, UB11 1B S, United Kingdom. David.J.Webb@GSK.com.
John LogieGSK Pharmaceuticals, Stockley Park West, 1-3 Ironbridge Road, Heathrow, Uxbridge, Middlesex, UB11 1B S, United Kingdom. John.W.Logie@GSK.com.
Gonçalo MatiasGSK Vaccines, Av Fleming 20, Parc de la Noire Epine, 1300, Wavre, Belgium. Gonzalo.X.Matias@gsk.com.
Sylvia TaylorGSK Vaccines, Av Fleming 20, Parc de la Noire Epine, 1300, Wavre, Belgium. Sylvia.M.Taylor@GSK.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGrowing evidence suggests respiratory syncytial virus (RSV) is an important cause of respiratory disease in adults. However, the adult burden remains largely uncharacterized as most RSV studies focus on children, and population-based studies with laboratory-confirmation of infection are difficult to implement. Indirect modelling methods, long used for influenza, can further our understanding of RSV burden by circumventing some limitations of traditional surveillance studies that rely on direct linkage of individual-level exposure and outcome data.

methodsMultiple linear time-series regression was used to estimate RSV burden in the United Kingdom (UK) between 1995 and 2009 among the total population and adults in terms of general practice (GP) episodes (counted as first consultation ≥28 days following any previous consultation for same diagnosis/diagnostic group), hospitalisations, and deaths for respiratory disease, using data from Public Health England weekly influenza/RSV surveillance, Clinical Practice Research Datalink, Hospital Episode Statistics, and Office of National Statistics. The main outcome considered all ICD-listed respiratory diseases and, for GP episodes, related symptoms. Estimates were adjusted for non-specific seasonal drivers of disease using secular cyclical terms and stratified by age and risk group (according to chronic conditions indicating severe influenza risk as per UK recommendations for influenza vaccination). Trial registration NCT01706302 . Registered 11 October 2012.

resultsAmong adults aged 18+ years an estimated 487,247 GP episodes, 17,799 hospitalisations, and 8,482 deaths were attributable to RSV per average season. Of these, 175,070 GP episodes (36 %), 14,039 hospitalisations (79 %) and 7,915 deaths (93 %) were in persons aged 65+ years. High- versus low-risk elderly were two-fold more likely to have a RSV-related GP episode or death and four-fold more likely be hospitalised for RSV. In most seasons since 2001, more GP episodes, hospitalisations and deaths were attributable to RSV in adults than to influenza.

conclusionRSV is associated with a substantial disease burden in adults comparable to influenza, with most of the hospitalisation and mortality burden in the elderly. Treatment options and measures to prevent RSV could have a major impact on the burden of RSV respiratory disease in adults, especially the elderly.

Indexed as

AdolescentAdultAgedChronic DiseaseDatabases, FactualFemaleHospitalizationHumansInfluenza, HumanInfluenza VaccinesLinear ModelsMaleMiddle AgedRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsSeasonsInfluenza Vaccines

Identifiers

PMID26497750
PMCPMC4618996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.